CD274 and non-small cell lung carcinoma: In the GEMSTONE-302 trial, patients with squamous or non-squamous NSCLC were randomized to receive either sugemalimab (a PD-L1 inhibitor) plus carboplatin-paclitaxel or carboplatin-pemetrexed, respectively, or placebo plus the same carboplatin-based regimens3.